Breaking News, Collaborations & Alliances

Heptares Gets $12mn AstraZeneca Milestone

Immuno-oncology collaboration focused on treatment for a range of cancers

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Heptares Therapeutics has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers. As a result, Heptares has been notified today that the achievement has triggered a $12 million payment from AstraZeneca. AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor antagonist discovered by Heptares and licensed to AstraZeneca...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters